VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma

Yao, X; Tan, J; Lim, K; Koh, J; Ooi, W; Li, Z; Huang, D; Xing, M; Chan, Y; Qu, J; Tay, S; Wijaya, G; Lam, Y; Hong, J; Lee-Lim, A; Guan, P; Ng, M; He, C; Lin, J; Nandi, T; Qamra, A; Xu, C; Myint, S; Davies, J; Goh, J; Loh, G; Tan, B; Rozen, S; Yu, Q; Tan, I; Cheng, C; Li, S; Chang, K; Tan, P; Silver, D; Lezhava, A; Steger, G; Hughes, J; Teh, B; Tan, P

Journal article

VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma

Abstract:: Protein-coding mutations in clear cell renal cell carcinoma (ccRCC) have been extensively characterized, frequently involving inactivation of the von Hippel–Lindau (VHL) tumor suppressor. Roles for noncoding cis-regulatory aberrations in ccRCC tumorigenesis, however, remain unclear. Analyzing 10 primary tumor/normal pairs and 9 cell lines across 79 chromatin profiles, we observed pervasive enhancer malfunction in ccRCC, with cognate enhancer-target genes associated with tissue-specific aspects of malignancy. Superenhancer profiling identified ZNF395 as a ccRCC-specific and VHL-regulated master regulator whose depletion causes near-complete tumor elimination in vitro and in vivo. VHL loss predominantly drives enhancer/superenhancer deregulation more so than promoters, with acquisition of active enhancer marks (H3K27ac, H3K4me1) near ccRCC hallmark genes. Mechanistically, VHL loss stabilizes HIF2α–HIF1β heterodimer binding at enhancers, subsequently recruiting histone acetyltransferase p300 without overtly affecting preexisting promoter–enhancer interactions. Subtype-specific driver mutations such as VHL may thus propagate unique pathogenic dependencies in ccRCC by modulating epigenomic landscapes and cancer gene expression.

Significance: Comprehensive epigenomic profiling of ccRCC establishes a compendium of somatically altered cis-regulatory elements, uncovering new potential targets including ZNF395, a ccRCC master regulator. Loss of VHL, a ccRCC signature event, causes pervasive enhancer malfunction, with binding of enhancer-centric HIF2α and recruitment of histone acetyltransferase p300 at preexisting lineage-specific promoter–enhancer complexes.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Yao, X., Tan, J., Lim, K., Koh, J., Ooi, W., Li, Z., Huang, D., Xing, M., Chan, Y., Qu, J., Tay, S., Wijaya, G., Lam, Y., Hong, J., Lee-Lim, A., Guan, P., Ng, M., He, C., Lin, J., … Tan, P. (2017). VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discovery, 7(11), 1284–1305.

MLA Style

Yao, X., et al. “VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma.” Cancer Discovery, vol. 7, no. 11, American Association for Cancer Research, 2017, pp. 1284–305.

Chicago Style

Yao, X, J Tan, K Lim, J Koh, W Ooi, Z Li, D Huang, et al. 2017. “VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma.” Cancer Discovery 7 (11): 1284–1305.
Share
Print